

A full list of abstract titles and viewing details are listed below

Abstract Title	Author	Presentation Type/#	Session Title	Session Date/Time (EST)
Pirtobrutinib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study	Chan Cheah	Oral Abstract #226	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM	Saturday, Dec. 6 2:45-3 p.m. EST
Real-world treatment patterns, patient characteristics, and outcomes of cBTKi-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States	Kami Maddocks	Poster Abstract #2725	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I	Saturday, Dec. 6 5:30-7:30 p.m. EST
Real-world characteristics, treatment patterns and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent Bruton tyrosine kinase inhibitors (cBTKi) in China	Yuin Song	Poster Abstract #2704	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I	Saturday, Dec. 6 5:30-7:30 p.m. EST
Pirtobrutinib in post-cBTKi CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up	William Wierda	Poster Abstract #2115	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I	Saturday, Dec. 6 5:30-7:30 p.m. EST
Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): final update from the Phase 1/2 BRUIN study	Michael Wang	Oral Abstract #665	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma	Sunday, Dec. 7 5:30-5:45 p.m. EST
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized Phase 3 study comparing a non-covalent and covalent BTK inhibitor	Jennifer Woyach	Oral Abstract #683	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL	Sunday, Dec. 7 5:30-5:45 p.m. EST
Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials	Toby Eyre	Poster Abstract #5684	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	Monday, Dec. 8 6-8 p.m. EST

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies	Toby Eyre	Poster Abstract #5670	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	Monday, Dec. 8 6-8 p.m. EST
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized Phase 3 study examining a non-covalent BTK inhibitor in untreated patients	Wojciech Jurczak	Oral Abstract #LBA-3	Late-Breaking Abstracts Session	Tuesday, Dec. 9 8-8:15 a.m. EST
Investigator-Initiated				
Pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation: A Phase 2 trial	Nitin Jain	Oral Abstract #89	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation	Saturday, Dec. 6 10:30-10:45 a.m. EST
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter Phase 2 study	Jorge Castillo	Oral Abstract #225	623. Mantle Cell, Follicular, Waldenström's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM	Saturday, Dec. 6 2:30-2:45 p.m. EST
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia	Nitin Jain	Oral Abstract #680	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL	Sunday, Dec. 7 4:45-5 p.m. EST
Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)	Sonia Rodriguez-Rodriguez	Poster Abstract #3878	641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II	Sunday, Dec. 7 6-8 p.m. EST
Pirtobrutinib versus usual care for patients with Richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort	Yucai Wang	Poster Abstract #5673	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	Monday, Dec. 8 6-8 p.m. EST